GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (HKSE:02268) » Definitions » ROE %

WuXi XDC Cayman (HKSE:02268) ROE % : 23.07% (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. WuXi XDC Cayman's annualized net income for the quarter that ended in Jun. 2023 was HK$422 Mil. WuXi XDC Cayman's average Total Stockholders Equity over the quarter that ended in Jun. 2023 was HK$1,831 Mil. Therefore, WuXi XDC Cayman's annualized ROE % for the quarter that ended in Jun. 2023 was 23.07%.

The historical rank and industry rank for WuXi XDC Cayman's ROE % or its related term are showing as below:

HKSE:02268' s ROE % Range Over the Past 10 Years
Min: 7   Med: 14.43   Max: 28.57
Current: 7

During the past 4 years, WuXi XDC Cayman's highest ROE % was 28.57%. The lowest was 7.00%. And the median was 14.43%.

HKSE:02268's ROE % is ranked better than
71.3% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: -6.44 vs HKSE:02268: 7.00

WuXi XDC Cayman ROE % Historical Data

The historical data trend for WuXi XDC Cayman's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi XDC Cayman ROE % Chart

WuXi XDC Cayman Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROE %
7.00 28.57 20.71 8.14

WuXi XDC Cayman Quarterly Data
Dec20 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23
ROE % Get a 7-Day Free Trial - - 21.26 23.07 -

Competitive Comparison of WuXi XDC Cayman's ROE %

For the Diagnostics & Research subindustry, WuXi XDC Cayman's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi XDC Cayman's ROE % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's ROE % distribution charts can be found below:

* The bar in red indicates where WuXi XDC Cayman's ROE % falls into.



WuXi XDC Cayman ROE % Calculation

WuXi XDC Cayman's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=310.128/( (1653.608+5965.816)/ 2 )
=310.128/3809.712
=8.14 %

WuXi XDC Cayman's annualized ROE % for the quarter that ended in Jun. 2023 is calculated as

ROE %=Net Income (Q: Jun. 2023 )/( (Total Stockholders Equity (Q: Mar. 2023 )+Total Stockholders Equity (Q: Jun. 2023 ))/ count )
=422.388/( (1803.436+1857.919)/ 2 )
=422.388/1830.6775
=23.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2023) net income data. ROE % is displayed in the 30-year financial page.


WuXi XDC Cayman  (HKSE:02268) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=422.388/1830.6775
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(422.388 / 2213.268)*(2213.268 / 2976.368)*(2976.368 / 1830.6775)
=Net Margin %*Asset Turnover*Equity Multiplier
=19.08 %*0.7436*1.6258
=ROA %*Equity Multiplier
=14.19 %*1.6258
=23.07 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=422.388/1830.6775
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (422.388 / 492.58) * (492.58 / 387.392) * (387.392 / 2213.268) * (2213.268 / 2976.368) * (2976.368 / 1830.6775)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8575 * 1.2715 * 17.5 % * 0.7436 * 1.6258
=23.07 %

Note: The net income data used here is four times the quarterly (Jun. 2023) net income data. The Revenue data used here is four times the quarterly (Jun. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


WuXi XDC Cayman ROE % Related Terms

Thank you for viewing the detailed overview of WuXi XDC Cayman's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi XDC Cayman (HKSE:02268) Business Description

Comparable Companies
Traded in Other Exchanges
Address
No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN
Website
WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.

WuXi XDC Cayman (HKSE:02268) Headlines

No Headlines